Targeting OLFML3 with monoclonal and recombinant antibodies inhibits tumor angiogenesis and tumor growth and has two notable advantages over anti-VEGF-A therapy: it disrupts the pericyte coverage of endothelial cells, targets angiogenic endothelial cells themselves, and prevents a compensatory proangiogenic response. This evidence concerns the gene VEGFA and neoplasm.